ClinicalTrials.gg
CompletedNCT03400189Updated Feb 18, 2020

Pharmacokinetics and Tolerability of Sulthiame

A Phase 1 interventional study of Sulthiame in Epilepsy, sponsored by Centre Hospitalier Universitaire Vaudois. Completed at 1 site in Switzerland. Open to male participants aged 18 Years to 45 Years, including healthy volunteers. Per ClinicalTrials.gov, last updated 2020-02-18.

Sponsored by Centre Hospitalier Universitaire Vaudois · Phase 1, Interventional, and Other

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 1
Study type
Interventional
Enrollment
4
Allocation
Not applicable
Ages
18 Years to 45 Years
Sex
Male
01

Where this study stands

Counted across the records on this site · 2026-11-18

Among 37 studies in Epilepsy with a site in Switzerland — 10 open to participants now, 11 under way, 1 of them phase 3. Epilepsy · Switzerland.

Enrollment
26th of 27
4 · median 120
Started
2018
with 2 others
Phase 1
Only one
of the 37
Registered
18th of 37
by date
Lead sponsor
2 of 37
Centre Hospitalier Universitaire Vaudois

Among the 37 studies in Epilepsy with a site in Switzerland, this one is the 26th largest by enrollment of the 27 interventional ones that give a count, is one of 3 that started in 2018, is the only one in phase 1, and was the 18th registered.

Epilepsy

1,848 studies on the registry are indexed under Epilepsy; 418 are open to participants now.

Browse Epilepsy studies →

Open to participants now

10 of the 37 studies in Epilepsy with a site in Switzerland are open now. Recruiting first, the newest first:

5 more — sign in →

All 10 open studies →

A study can be open while its sites in Switzerland have not opened yet or have stopped. Only those recruiting at a site in Switzerland →

Who these studies take

Of the 283 Epilepsy studies recruiting now, 113 (40%) set no upper age limit and 147 (52%) stop at 75 or younger; 138 take children under 18; 55 take healthy volunteers.

This study: 18 Years to 45 Years · male · healthy volunteers too.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 37 studies in Epilepsy with a site in Switzerland, or all of them as a file.
02

Study summary

This preliminary pilot exploration aims at specifying the pharmacokinetic parameters of sulthiame, formulated as an immediate release tablet, thus helping to design proper clinical trials for the future assessment of new paediatric formulations currently under development. The clinical tolerability to single doses of sulthiame will also be closely monitored to orient future trials.

Read the detailed description

Sulthiame (or sultiame), marketed in the 60's in Germany, Austria, Switzerland, Israel, Australia and Japan under the brand name Ospolot®, has progressively become the therapeutic first choice in benign focal epilepsies of childhood in these countries.

Its antiepileptic activity is thought to result from the inhibition of various subtypes of carbonic anhydrase (hCA), in particular cytosolic hCA II, thus inducing a degree of intracellular acidification sufficient to stabilize seizure-eliciting neurons. The pharmacokinetic profile of sulthiame was scarcely studied in humans.

Sulthiame is a suitable candidate for paediatric formulation optimization, as the current formulation (coated tablets of 50 or 200 mg) allows neither precise and adapted dosing, nor convenient administration to young children.

03

Conditions studied

  • Epilepsy

Browse trials for

04

Who can participate

Ages eligible
18 Years to 45 Years
Sexes eligible
Male
Accepts healthy volunteers
Yes

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  1. Healthy male subjects aged between 18 and 45 years.
  2. Body weight (BW) ranging between 55 and 95 kg, providing (BMI) is between 18 and 29 kg/m2
  3. Absence of significant findings in the medical history and physical examination as judged by the Investigator, especially for cardiovascular, pulmonary, haematological and nervous systems
  4. Absence of significant laboratory abnormalities as judged by the Investigator. Gilbert's syndrome (increased total and unconjugated when fasting) will be accepted if mild
  5. Absence of abnormalities on 12-lead (ECG)
  6. Negative urine drug screen (amphetamines, benzodiazepines, cannabis, cocaine, opiates)
  7. Commitment to refrain from travels outside Europe over the whole study duration.
  8. Ability to understand the procedures, agreement to participate and willingness to give written
  9. Co-operative attitude and availability for scheduled visits over the entire study period.

Exclusion criteria

Exclusion Criteria:

  1. History of major cardiovascular, pulmonary, hepatic, immunological, renal, haematological, gastrointestinal, genitourinary, neurological, or rheumatologic disorders
  2. Active diseases of any type, including inflammatory disorders and infections. Mild acne is permissible providing no systemic or local treatment is provided or planned (except for cleaning lotions)
  3. History of significant allergy or asthma. Allergic rhinitis or conjunctivitis is acceptable if non symptomatic when starting the study and if symptoms are not anticipated to occur during the study to a point that would require therapy (e.g. in case of annual use)
  4. History of cardiovascular dysfunction if considered as (conduction abnormality, arrhythmia, bradycardia, angina pectoris, cardiac hypertrophy unless elicited by training, pulmonary embolism)
  5. Hypertension defined as supine blood pressure >150/90 mmHg or recurrent hypotensive events considered as clinically relevant or documented orthostatic hypotension
  6. Sick sinus syndrome, known long syndrome, reproducible observation of QTc >440 msec or of pronounced sinus bradycardia (\<40 bpm/min)
  7. Intense sport activities. Moderate sport is acceptable and activities should remain fairly constant throughout the study
  8. Any clinically significant laboratory value on screening that are not within normal range on single repeat (Gilbert's syndrome acceptable if mild)
  9. Positive \& C antigen screen
  10. Positive antibody screen or screen not performed
  11. Any recent acute illness or sequelae thereof which could expose the subject to a higher risk or might confound the results of the study
  12. Treatment in the previous three months with any drug known to have well-defined potential for toxicity to a major organ
  13. History of to any drug if considered as serious including sulthiame or the of the study formulation
  14. Use of any medication the week prior to study or as based on 5 plasma half-life rule and throughout study, including aspirin or other over-the-counter (OTC) preparation. Paracetamol is permissible before and during study as a concomitant medication but only with Investigator's permission.
  15. Participation in a clinical investigation or blood donation of 500 ml within the past 3 months
  16. History of relevant alcohol or drug abuse
  17. Smoking. Consumption of \<5 cigarettes/day or equivalent is acceptable providing the subject can refrain from smoking from one week before and during the whole study duration
  18. Consumption of a large quantity of coffee, tea, chocolate (more than 4 cups/day) or equivalent (Cola drinks)
  19. Present consumption of a large quantity of alcohol or wine (>0.5 L wine/day) or equivalent, (equivalent to more than >48 g ethanol per day).
  20. Project to conceive a child during the study period (by principle of precaution, while no indication exists for a definite reproductive risk following paternal exposure)
  21. Psychological status which could impact on subject's ability to give
  22. Any feature of subject's medical history or present condition which, in the Investigator's opinion, could confound the results of the study, complicate its interpretation, or represent a potential risk for the subject.
Terms in these criteria, in plain language(11)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

BMI (body mass index)

Weight in kilograms divided by height in metres squared. Example: 70 kg and 1.75 m gives 70 ÷ (1.75 × 1.75) ≈ 22.9.

What counts as overweight or obesity differs between countries (some use lower cut-offs), so go by the range the study states.

Bilirubin

A yellow substance made when red blood cells are broken down, which the liver clears. A high level can mean a problem with the liver or the bile ducts.

Criteria often allow more for people with Gilbert’s syndrome, a harmless inherited condition that raises bilirubin.

Clinically significant

Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.

ECG (electrocardiogram)

A recording of the heart’s electrical activity, taken with stickers on the chest, arms and legs. It takes a few minutes and does not hurt.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

Corticosteroids (steroids)

Anti-inflammatory medicines such as prednisone, prednisolone and dexamethasone — not the anabolic steroids used for muscle.

Studies differ in what they allow: check which steroid medicines, routes (tablets, injections, creams, inhalers, eye drops) and doses this study accepts.

QT and QTc

On an ECG, the QT interval is the time the heart’s lower chambers take to activate electrically and recover in each beat. QTc is that time adjusted for heart rate (QTcF by Fridericia’s formula, QTcB by Bazett’s). Some medicines lengthen it, and a long QTc can raise the risk of a dangerous heart rhythm.

The study may name a correction formula and a limit in milliseconds, often around 450–480.

Hepatitis B tests

Hepatitis B is a virus that infects the liver. These are separate tests: HBsAg positive usually means a current infection (a recent vaccination can briefly cause it too); total anti-HBc (HBcAb) positive means an infection now or in the past; HBV DNA measures how much virus is in the blood.

Some studies accept a past infection if HBV DNA is undetectable, sometimes with antiviral medicine during the study. Check what this study allows.

HIV

The human immunodeficiency virus, which weakens the immune system.

Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.

Hypersensitivity

An allergy, or another reaction of the immune system, to a substance. “Hypersensitivity to the study drug” means a known allergic reaction to it — not every side effect a medicine can have.

Excipients

The other ingredients in a medicine besides the active drug, such as fillers, colors or preservatives.

05

Study design

Phase
Phase 1
Primary purpose
Other
Allocation
Not applicable
Intervention model
Single group
Masking
None (open label)
Enrollment
4 participants (actual)

Study arms

  • Other
    Single arm

    Single oral dose of sulthiame (Ospolot® tablets) * Period I: 50 mg * Period II: 100 mg * Period III: 200 mg given 3 weeks apart

    Drug: Sulthiame

Interventions

  • Single dose (50, 100, 200 mg)

    Also known as: Ospolot

06

What researchers measure

Primary outcomes

  1. Elimination half-life of sultiame after single doses of 50, 100 and 200 mg of sulthiame in 4 healthy volunteers.

    Sultiame plasma concentration will be measured at predefined times after dose administration, the results will be plotted graphically and traditional pharmacokinetic calculations (log-linear regression) will be used to derive estimates of this pharmacokinetic parameter. This is a descriptive outcome and no statistical test is applied.

    Time frame: 9 weeks

  2. Area Under curve (AUC) of sultiame after single doses of 50, 100 and 200 mg of sulthiame in 4 healthy volunteers.

    Sultiame plasma concentration will be measured at predefined times after dose administration, the results will be plotted graphically and traditional pharmacokinetic calculations (numerical integration through trapezoidal rule) will be used to derive estimates of this pharmacokinetic parameter. This is a descriptive outcome and no statistical test is applied.

    Time frame: 9 weeks

  3. Systemic drug clearance of sultiame after single doses of 50, 100 and 200 mg of sulthiame in 4 healthy volunteers.

    Sultiame concentration will be measured at predefined times after dose administration, the results will be plotted graphically and traditional pharmacokinetic calculations (ratio of administered dose over AUC) will be used to derive estimates of this pharmacokinetic parameter. This is a descriptive outcome and no statistical test is applied.

    Time frame: 9 weeks

  4. Distribution volume of sultiame after single doses of 50, 100 and 200 mg of sulthiame in 4 healthy volunteers.

    Sultiame plasma concentration will be measured at predefined times after dose administration, the results will be plotted graphically and traditional pharmacokinetic calculations (product of clearance by half-life divided by the logarithm of 2) will be used to derive estimates of this pharmacokinetic parameter. This is a descriptive outcome and no statistical test is applied.

    Time frame: 9 weeks

Secondary outcomes

  1. Dose linearity of plasma exposure to sultiame

    A linear regression model will be applied to AUC as a function of dose, and the conclusion of dose linearity will be accepted if the model appears statistically non-inferior to an ANOVA model.

    Time frame: 9 weeks

  2. Plasma free fraction of sultiame

    The ratios of free over total plasma concentrations, and of whole blood over total plasma concentrations will be calculated, and its stability over the range of concentrations will be checked by statistical analysis for trend.

    Time frame: 9 weeks

  3. Erythrocyte binding of sultiame

    The ratios of free over total plasma concentrations, and of whole blood over total plasma concentrations will be calculated, and its stability over the range of concentrations will be checked by statistical analysis for trend.

    Time frame: 9 weeks

  4. Validation of a liquid chromatography-mass spectrometry (LC-MS/MS) assay method for the determination of sultiame in biological fluids

    The analytical method used for the study will be assessed for its sensitivity (estimation of detection and quantification limits), precision (estimation of intra-day and inter-day reproducibility) and accuracy (estimation of sultiame recovery using spiked samples). The analytical method will be considered validated if all criteria are within the acceptance range set by FDA/ICH recommendations.

    Time frame: 9 weeks

07

Study locations

1 site
  • Division of Clinical Pharmacology
    Lausanne, Vaud 1011, Switzerland
08

References and documents

Individual participant data

Plan to share: Undecided

No publications or documents are linked to this record.

09

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Ran from Feb 2018 to primary completion in May 2018, 3 months.

Of 55 phase 1 interventional studies under Epilepsy, half reached primary completion within 8 months of starting (the median), counting those still running; a quarter within 3 and three quarters within 22. This study's 3 months is below that.

How these figures are worked out, and which studies are left out of them.

Registered
Dec 14, 2017
First posted
Jan 17, 2018
StartActual
Feb 12, 2018
Primary completionActual
May 22, 2018
CompletionActual
Aug 30, 2018
Last update
Feb 18, 2020
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Feb 18, 2020, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT03400189
Collaborators
Advicenne Pharma
Responsible party
Thierry Buclin (Professor, Centre Hospitalier Universitaire Vaudois) — Principal investigator
First posted
Jan 17, 2018
Start date
Feb 12, 2018
Primary completion
May 22, 2018
Completion
Aug 30, 2018
Last update
Feb 18, 2020

Oversight

Data monitoring committee
Yes
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Feb 2020. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Sulthiame

Start the discussion